POLUZZI, ELISABETTA
POLUZZI, ELISABETTA
DIPARTIMENTO DI SCIENZE MEDICHE E CHIRURGICHE
Docenti di ruolo di Ia fascia
Adopting STOPP/START Criteria Version 3 in Clinical Practice: A Q&A Guide for Healthcare Professionals
2024 Lunghi C.; Domenicali M.; Vertullo S.; Raschi E.; De Ponti F.; Onder G.; Poluzzi E.
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS
2024 Fusaroli M.; Giunchi V.; Battini V.; Puligheddu S.; Khouri C.; Carnovale C.; Raschi E.; Poluzzi E.
Environmentally sustainable prescribing: recommendations for EU pharmaceutical legislation
2024 Piët J.D.; Booth A.; Donker E.M.; de Ponti F.; Lunghi C.; Poluzzi E.; Janssen B.J.A.; Tun S.Y.M.; Bekker C.; Dima L.; Costa J.; Jalving M.; Oude Munnink T.H.; van den Bemt P.M.L.A.; Labriffe M.; van Emden T.; van Waardenburg V.; Likic R.; Richir M.; van Agtmael M.A.; Moermond C.T.A.; Tichelaar J.
Learning of clinical pharmacology by future prescribers in Bologna: Teachers' and students' reflections on the way forward
2024 Poluzzi E.; Raschi E.; Lunghi C.; Bertuccio A.; Eleftheriou A.; De Ponti F.
Behavioral excess and disruptive conduct: A historical and taxonomic approach to the origin of the ‘impulse control disorders’ diagnostic construct
2023 Fusaroli M.; Pellegrini L.; Fusaroli R.; Raschi E.; Menchetti M.; Poluzzi E.
Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative Approach
2023 Giunchi, Valentina; Fusaroli, Michele; Hauben, Manfred; Raschi, Emanuel; Poluzzi, Elisabetta
Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System
2023 Fusaroli M.; Pelletti G.; Giunchi V.; Pugliese C.; Bartolucci M.; Necibi E.N.; Raschi E.; De Ponti F.; Pelotti S.; Poluzzi E.
Editorial: Pharmacovigilance and drug repositioning research using pharmacoepidemiology
2023 Noguchi Y.; Yan M.; Yokoyama S.; Poluzzi E.
Exploring the underlying mechanisms of drug-induced impulse control disorders: a pharmacovigilance-pharmacodynamic study
2023 Fusaroli M.; Giunchi V.; Battini V.; Gringeri M.; Rimondini R.; Menchetti M.; Radice S.; Pozzi M.; Nobile M.; Clementi E.; De Ponti F.; Carnovale C.; Raschi E.; Poluzzi E.
Identifying Medications Underlying Communication Atypicalities in Psychotic and Affective Disorders: A Pharmacovigilance Study Within the FDA Adverse Event Reporting System
2023 Fusaroli M.; Simonsen A.; Borrie S.A.; Low D.M.; Parola A.; Raschi E.; Poluzzi E.; Fusaroli R.
Impact of regulatory restrictions on the use of valproic acid in women of childbearing age: An Italian study
2023 DiVito L.; Mazzoni S.; Belotti L.M.B.; Poluzzi E.; Baldin E.; Zenesini C.; Bisulli F.; Tinuper P.; Mostacci B.
Mapping Strategies to Assess and Increase the Validity of Published Disproportionality Signals: A Meta-Research Study
2023 Fusaroli M.; Salvo F.; Bernardeau C.; Idris M.; Dolladille C.; Pariente A.; Poluzzi E.; Raschi E.; Khouri C.
Medication use in Italian nursing homes: preliminary results from the national monitoring system
2023 Zito S.; Poluzzi E.; Pierantozzi A.; Onder G.; Da Cas R.; Ippoliti I.; Lunghi C.; Cangini A.; Trotta F.
Safety of COVID-19 Vaccines Among the Paediatric Population: Analysis of the European Surveillance Systems and Pivotal Clinical Trials
2023 Ahmadizar F.; Luxi N.; Raethke M.; Schmikli S.; Riefolo F.; Saraswati P.W.; Bucsa C.; Osman A.; Liddiard M.; Maques F.B.; Petrelli G.; Sonderlichova S.; Thurin N.H.; Villalobos F.; Trifiro G.; Sturkenboom M.; Moretti U.; Bellitto C.; Ciccimarra F.; Gonella L.A.; Arzenton E.; Chiamulera C.; Lora R.; Bellantuono D.; Sabaini A.; Firenze A.; Zodda D.; Guidotti F.; Zappone M.; Alagna B.; Cutroneo P.M.; Minore C.; Costantino C.; Vitale F.; D'Alessandro G.; Morreale I.; Marsala L.; Farinella D.; Bavetta S.; Fantini M.P.; Reno C.; Raschi E.; Poluzzi E.; Sapigni E.; Potenza A.M.; Podetti D.; Nikitina V.; Ricciardelli R.; Mogheiseh N.; Croce S.; Paltrinieri B.; Castellani S.; Sangiorgi E.; Selleri M.; Lucchesi S.; Catucci G.; Savini D.; Sacripanti C.; Faccioli M.; Romio M.S.; Rossi L.; Radici S.; Negri G.; Fares L.; Ajolfi C.; Fadda A.; Chiarello A.; Pieraccini F.; Gavioli B.; Palazzi S.; Tuccori M.; Vannacci A.; Bonaiuti R.; Ravaldi C.; Lombardi N.; Crescioli G.; Gori F.; Tessari R.; Zandona E.; Zanoni G.; Senna G.; Crivellaro M.A.; Cancian M.; Venturini F.; Ferri M.; Leonardi L.; Orzetti S.; Caccin E.; Baldo P.; Capuano A.; Rafaniello C.; Ferrajolo C.; Pagliaro C.; Mercaldo M.; di Giorgio A.; Tari M.; Manna S.; Farina G.; Di Mauro C.; De Carlo I.; Senesi I.; Pileggi C.; Palleria C.; Gallelli L.; De Sarro G.; de Sarro C.; Verduci C.; Papadopoli R.; Trabace L.; Morgese M.; Schiavone S.; Tucci P.; Bove M.; Lapi F.; Cricelli C.; Racagni G.; Tonolo S.; Fava G.; Giuffrida S.; Amato V.; Gambera M.; Montresor V.; Mastropasqua D.
Spotlight commentary: The value of spontaneous reporting systems to detect (the lack of) clinically relevant drug–drug interactions in clinical practice
2023 Raschi, Emanuel; Poluzzi, Elisabetta; De Ponti, Fabrizio
The environmental impact of pharmaceuticals in Italy: Integrating healthcare and eco-toxicological data to assess and potentially mitigate their diffusion to water supplies
2023 Giunchi V.; Fusaroli M.; Linder E.; Villén J.; Wettermark B.; Nekoro M.; Raschi E.; Lunghi C.; Poluzzi E.
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System
2022 Raschi E.; Fusaroli M.; Giunchi V.; Repaci A.; Pelusi C.; Mollica V.; Massari F.; Ardizzoni A.; Poluzzi E.; Pagotto U.; Di Dalmazi G.
Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System
2022 Gaimari A.; Fusaroli M.; Raschi E.; Baldin E.; Vignatelli L.; Nonino F.; De Ponti F.; Mandrioli J.; Poluzzi E.
Comparison of drug prescribing before and during the COVID-19 pandemic: A cross-national European study
2022 Selke Krulichova I.; Selke G.W.; Bennie M.; Hajiebrahimi M.; Nyberg F.; Furst J.; Garuoliene K.; Poluzzi E.; Slaby J.; Yahni C.Z.; Altini M.; Fantini M.P.; Koci V.; McTaggart S.; Pontes C.; Reno C.; Rosa S.; Pedrola M.T.; Udovic M.; Wettermark B.
Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems
2022 Gatti M.; Fusaroli M.; Raschi E.; Capelli I.; Poluzzi E.; De Ponti F.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Adopting STOPP/START Criteria Version 3 in Clinical Practice: A Q&A Guide for Healthcare Professionals | Lunghi C.; Domenicali M.; Vertullo S.; Raschi E.; De Ponti F.; Onder G.; Poluzzi E. | 2024-01-01 | DRUG SAFETY | - | 1.01 Articolo in rivista | Lunghi et al. Drug Safety 2024.pdf; 40264_2024_1453_MOESM1_ESM.pdf |
| Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS | Fusaroli M.; Giunchi V.; Battini V.; Puligheddu S.; Khouri C.; Carnovale C.; Raschi E.; Poluzzi E. | 2024-01-01 | DRUG SAFETY | - | 1.01 Articolo in rivista | s40264-023-01391-4.pdf; 40264_2023_1391_MOESM1_ESM.docx |
| Environmentally sustainable prescribing: recommendations for EU pharmaceutical legislation | Piët J.D.; Booth A.; Donker E.M.; de Ponti F.; Lunghi C.; Poluzzi E.; Janssen B.J.A.; Tun S.Y.M.;... Bekker C.; Dima L.; Costa J.; Jalving M.; Oude Munnink T.H.; van den Bemt P.M.L.A.; Labriffe M.; van Emden T.; van Waardenburg V.; Likic R.; Richir M.; van Agtmael M.A.; Moermond C.T.A.; Tichelaar J. | 2024-01-01 | THE LANCET. PLANETARY HEALTH | - | 1.04 Replica / breve intervento (e simili) | - |
| Learning of clinical pharmacology by future prescribers in Bologna: Teachers' and students' reflections on the way forward | Poluzzi E.; Raschi E.; Lunghi C.; Bertuccio A.; Eleftheriou A.; De Ponti F. | 2024-01-01 | BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | - | 1.01 Articolo in rivista | - |
| Behavioral excess and disruptive conduct: A historical and taxonomic approach to the origin of the ‘impulse control disorders’ diagnostic construct | Fusaroli M.; Pellegrini L.; Fusaroli R.; Raschi E.; Menchetti M.; Poluzzi E. | 2023-01-01 | ADDICTION | - | 1.01 Articolo in rivista | Behavioral excess and disruptive conduct A historical and taxonomic approach to the origin of the 'impulse control disorders' diagnostic construct.pdf |
| Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative Approach | Giunchi, Valentina; Fusaroli, Michele; Hauben, Manfred; Raschi, Emanuel; Poluzzi, Elisabetta | 2023-01-01 | DRUG SAFETY | - | 1.01 Articolo in rivista | - |
| Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System | Fusaroli M.; Pelletti G.; Giunchi V.; Pugliese C.; Bartolucci M.; Necibi E.N.; Raschi E.; De Pont...i F.; Pelotti S.; Poluzzi E. | 2023-01-01 | DRUG SAFETY | - | 1.01 Articolo in rivista | s40264-022-01269-x.pdf; 40264_2022_1269_MOESM1_ESM.pdf |
| Editorial: Pharmacovigilance and drug repositioning research using pharmacoepidemiology | Noguchi Y.; Yan M.; Yokoyama S.; Poluzzi E. | 2023-01-01 | FRONTIERS IN PHARMACOLOGY | - | 1.04 Replica / breve intervento (e simili) | fphar-14-1225909.pdf |
| Exploring the underlying mechanisms of drug-induced impulse control disorders: a pharmacovigilance-pharmacodynamic study | Fusaroli M.; Giunchi V.; Battini V.; Gringeri M.; Rimondini R.; Menchetti M.; Radice S.; Pozzi M....; Nobile M.; Clementi E.; De Ponti F.; Carnovale C.; Raschi E.; Poluzzi E. | 2023-01-01 | PSYCHIATRY AND CLINICAL NEUROSCIENCES | - | 1.01 Articolo in rivista | Exploring the underlying mechanisms of drug-induced impulse control disorders a pharmacovigilance-pharmacodynamic study.pdf |
| Identifying Medications Underlying Communication Atypicalities in Psychotic and Affective Disorders: A Pharmacovigilance Study Within the FDA Adverse Event Reporting System | Fusaroli M.; Simonsen A.; Borrie S.A.; Low D.M.; Parola A.; Raschi E.; Poluzzi E.; Fusaroli R. | 2023-01-01 | JOURNAL OF SPEECH, LANGUAGE, AND HEARING RESEARCH | - | 1.01 Articolo in rivista | 2022.09.05.22279609v3.full.pdf |
| Impact of regulatory restrictions on the use of valproic acid in women of childbearing age: An Italian study | DiVito L.; Mazzoni S.; Belotti L.M.B.; Poluzzi E.; Baldin E.; Zenesini C.; Bisulli F.; Tinuper P....; Mostacci B. | 2023-01-01 | EPILEPSIA | - | 1.01 Articolo in rivista | - |
| Mapping Strategies to Assess and Increase the Validity of Published Disproportionality Signals: A Meta-Research Study | Fusaroli M.; Salvo F.; Bernardeau C.; Idris M.; Dolladille C.; Pariente A.; Poluzzi E.; Raschi E....; Khouri C. | 2023-01-01 | DRUG SAFETY | - | 1.01 Articolo in rivista | Fusaroli_2023.pdf; 40264_2023_1329_MOESM2_ESM.xlsx; 40264_2023_1329_MOESM1_ESM.pdf |
| Medication use in Italian nursing homes: preliminary results from the national monitoring system | Zito S.; Poluzzi E.; Pierantozzi A.; Onder G.; Da Cas R.; Ippoliti I.; Lunghi C.; Cangini A.; Tro...tta F. | 2023-01-01 | FRONTIERS IN PHARMACOLOGY | - | 1.01 Articolo in rivista | Zito et al. Frontiers in Pharmacology 2023.pdf; Data Sheet 3.docx |
| Safety of COVID-19 Vaccines Among the Paediatric Population: Analysis of the European Surveillance Systems and Pivotal Clinical Trials | Ahmadizar F.; Luxi N.; Raethke M.; Schmikli S.; Riefolo F.; Saraswati P.W.; Bucsa C.; Osman A.; L...iddiard M.; Maques F.B.; Petrelli G.; Sonderlichova S.; Thurin N.H.; Villalobos F.; Trifiro G.; Sturkenboom M.; Moretti U.; Bellitto C.; Ciccimarra F.; Gonella L.A.; Arzenton E.; Chiamulera C.; Lora R.; Bellantuono D.; Sabaini A.; Firenze A.; Zodda D.; Guidotti F.; Zappone M.; Alagna B.; Cutroneo P.M.; Minore C.; Costantino C.; Vitale F.; D'Alessandro G.; Morreale I.; Marsala L.; Farinella D.; Bavetta S.; Fantini M.P.; Reno C.; Raschi E.; Poluzzi E.; Sapigni E.; Potenza A.M.; Podetti D.; Nikitina V.; Ricciardelli R.; Mogheiseh N.; Croce S.; Paltrinieri B.; Castellani S.; Sangiorgi E.; Selleri M.; Lucchesi S.; Catucci G.; Savini D.; Sacripanti C.; Faccioli M.; Romio M.S.; Rossi L.; Radici S.; Negri G.; Fares L.; Ajolfi C.; Fadda A.; Chiarello A.; Pieraccini F.; Gavioli B.; Palazzi S.; Tuccori M.; Vannacci A.; Bonaiuti R.; Ravaldi C.; Lombardi N.; Crescioli G.; Gori F.; Tessari R.; Zandona E.; Zanoni G.; Senna G.; Crivellaro M.A.; Cancian M.; Venturini F.; Ferri M.; Leonardi L.; Orzetti S.; Caccin E.; Baldo P.; Capuano A.; Rafaniello C.; Ferrajolo C.; Pagliaro C.; Mercaldo M.; di Giorgio A.; Tari M.; Manna S.; Farina G.; Di Mauro C.; De Carlo I.; Senesi I.; Pileggi C.; Palleria C.; Gallelli L.; De Sarro G.; de Sarro C.; Verduci C.; Papadopoli R.; Trabace L.; Morgese M.; Schiavone S.; Tucci P.; Bove M.; Lapi F.; Cricelli C.; Racagni G.; Tonolo S.; Fava G.; Giuffrida S.; Amato V.; Gambera M.; Montresor V.; Mastropasqua D. | 2023-01-01 | DRUG SAFETY | - | 1.01 Articolo in rivista | Safety of COVID-19 Vaccines Among the Paediatric Population Analysis of the European Surveillance Systems and Pivotal Clinical Trials.pdf |
| Spotlight commentary: The value of spontaneous reporting systems to detect (the lack of) clinically relevant drug–drug interactions in clinical practice | Raschi, Emanuel; Poluzzi, Elisabetta; De Ponti, Fabrizio | 2023-01-01 | BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | - | 1.04 Replica / breve intervento (e simili) | - |
| The environmental impact of pharmaceuticals in Italy: Integrating healthcare and eco-toxicological data to assess and potentially mitigate their diffusion to water supplies | Giunchi V.; Fusaroli M.; Linder E.; Villén J.; Wettermark B.; Nekoro M.; Raschi E.; Lunghi C.; Po...luzzi E. | 2023-01-01 | BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | - | 1.01 Articolo in rivista | Brit J Clinical Pharma - 2023 - Giunchi - The environmental impact of pharmaceuticals in Italy Integrating healthcare and.pdf; 15761.zip |
| Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System | Raschi E.; Fusaroli M.; Giunchi V.; Repaci A.; Pelusi C.; Mollica V.; Massari F.; Ardizzoni A.; P...oluzzi E.; Pagotto U.; Di Dalmazi G. | 2022-01-01 | CANCERS | - | 1.01 Articolo in rivista | cancers-14-04610-v2 (2).pdf |
| Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System | Gaimari A.; Fusaroli M.; Raschi E.; Baldin E.; Vignatelli L.; Nonino F.; De Ponti F.; Mandrioli J....; Poluzzi E. | 2022-01-01 | DRUG SAFETY | - | 1.01 Articolo in rivista | Amyotrophic.pdf |
| Comparison of drug prescribing before and during the COVID-19 pandemic: A cross-national European study | Selke Krulichova I.; Selke G.W.; Bennie M.; Hajiebrahimi M.; Nyberg F.; Furst J.; Garuoliene K.; ...Poluzzi E.; Slaby J.; Yahni C.Z.; Altini M.; Fantini M.P.; Koci V.; McTaggart S.; Pontes C.; Reno C.; Rosa S.; Pedrola M.T.; Udovic M.; Wettermark B. | 2022-01-01 | PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | - | 1.01 Articolo in rivista | Comparison of drug prescribing before and during the COVID-19 pandemic: A cross-national European study.pdf; pds5509-sup-0001-supinfo.pdf |
| Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems | Gatti M.; Fusaroli M.; Raschi E.; Capelli I.; Poluzzi E.; De Ponti F. | 2022-01-01 | JN. JOURNAL OF NEPHROLOGY | - | 1.01 Articolo in rivista | 40620_2021_1191_MOESM2_ESM.pptx; 40620_2021_1191_MOESM1_ESM.pptx |